BOLETIN COVID- 19: Variantes

 

Agosto 2021


1. The variant gambit: COVID-19's next move. Cell Host Microbe. 2021;  29(4): 508-515. 

2. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 2021; 26(26). 

3. SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?. J Med Virol. 2021; 1-6

4. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; doi: 10.1038/s41586-021-03777-9.

5. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021; 184(9): 2384-2393.e12.

6. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; NEJMoa2108891.

7. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?. J Clin Med Res. 2021; 13(6): 317-325. 

8. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021; 593(7857): 136-141.

9. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021. doi: 10.1038/s41591-021-01446-y.

10. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021; 29(4): 516-521.e3.

11. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20): 1885-1898.

12. Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. Viruses. 2021; 13(7): 1347.

13. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nat Med. 2021; 27(7): 1230-1238.

14. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. Emerg Microbes Infect. 2021; 10(1): 1241-1243.

15. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021; 373(6555): 648-654.

16. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021; 596. doi: 10.1038/s41586-021-03693-y.

17. Genomic surveillance activities unveil the introduction of the SARS-CoV-2 B.1.525 variant of interest in Brazil: Case report. J Med Virol. 2021; 93(9): 5523-5526.

18. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nat Commun. 2021; 12(1): 4886.

19. The Emerging Concern and Interest SARS-CoV-2 Variants. Pathogens. 2021; 10(6): 633.

20. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021; 596(7870): 103-108.